InDex Pharmaceuticals announces expected cash balance per March 31, 2024
STOCKHOLM, Jan. 19, 2024 /PRNewswire/ — InDex Pharmaceuticals Holding AB (publ) (“InDex Pharmaceuticals”) today announced that remaining commitments for the company have been quantified, and the expected cash balance per March 31, 2024, amounts to SEK 180-190 million. The amount includes all closing costs for the phase III program CONCLUDE, even though activities for closing … Read more
